Current stock page

Financial Data

MDGL Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

MDGLMadrigal Pharmaceuticals, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$427.39+$2.18 (+0.51%)

Latest quote

  • Momentum
    40
  • Value
    66
  • Quality
    67
  • Risk resilience
    63
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$431.27M$364.25M$311.34M$321.08M$287.27M$212.8M$137.25M$103.32M
Gross Profit$393.45M$324.25M$284.49M$296.64M$269.15M$203.74M$132.74M$99.88M
Operating Income$55.99M-$56.31M-$92.72M-$59.61M-$113.98M-$47.2M-$79.31M-$67M
Net Income$55.44M-$57.94M-$94.39M-$58.58M-$114.19M-$42.28M-$73.24M-$59.42M
EPS$1.9-$1.99-$3.25-$2.57-$5.08-$1.9-$3.32-$2.71
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$120.56M$23.33M-$167.44M-$133.46M$79.85M-$47.05M-$88.89M-$104.49M
Capital Expenditure-$3.93M-$4.25M-$3.85M$390K-$857K$0$0-$195K
Free Cash Flow$116.63M$19.08M-$171.28M-$133.07M$78.99M-$47.05M-$88.89M-$104.68M
Net Cash Provided By Operating Activities$120.56M$23.33M-$167.44M-$133.46M$79.85M-$47.05M-$88.89M-$104.49M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.43B$1.24B$1.23B$1.26B$1.36B$1.02B$996.63M$1.04B
Total Debt$354.22M$347.75M$347.31M$354.36M$346.4M$123.95M$119.77M$119.57M
Cash And Cash Equivalents$514.64M$292.73M$232.19M$198.69M$295.69M$186.19M$183.65M$100.02M
Total Liabilities$807.45M$720.92M$683.87M$656.9M$736.73M$319.4M$285.99M$287.86M
Total Stockholders Equity$626.94M$523.72M$543.45M$602.69M$625.73M$695.98M$710.64M$754.38M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio19.3227.4428.8316.2615.9810.8110.1910.35
P/S ratio8.75———————
Debt To Equity0.560.660.640.590.550.180.170.16
Free Cash Flow Yield-1.39%-1.44%-1.74%-1.94%-1.62%-4.10%-5.54%-5.92%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio19.3227.4428.8316.2615.9810.8110.1910.35
P/S ratio8.75———————
Return On Equity-24.80%-62.07%-56.94%-47.83%-46.21%-40.50%-55.10%-61.76%
Debt To Equity0.560.660.640.590.550.180.170.16

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-72.32x
Pb19.94x
Revenue Growth Yoy50.13%
EPS Growth Yoy137.40%
Gross Margin90.96%
Operating Margin-10.69%
ROE-27.07%
ROIC-15.56%
Debt To Equity0.56
FCF Yield-1.70%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$427.39
Volume441,247
RSI (14)42.45
MACD-14.34
MACD signal-18.12
MACD histogram3.78
ADX (14)24.83
SMA (50)$475.72
SMA (200)$496.00
ATR (14)$21.75
Historical volatility (annualized)49.91%
Volume (20-day average)582,738

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score63/100
Beta0.41
Annual volatility42.57%
Max Drawdown-34.26%
Sharpe Ratio-0.32
VaR (95%, 1-day)-4.08%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

MDGL Financial Data FAQ

What is Madrigal Pharmaceuticals, Inc.'s revenue?

Madrigal Pharmaceuticals, Inc.'s revenue is one of the core financial data points for MDGL. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Madrigal Pharmaceuticals, Inc.'s revenue growing?

Revenue growth shows whether Madrigal Pharmaceuticals, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is MDGL's EPS?

MDGL's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Madrigal Pharmaceuticals, Inc.'s net income?

Madrigal Pharmaceuticals, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Madrigal Pharmaceuticals, Inc. generate?

Free cash flow shows how much cash Madrigal Pharmaceuticals, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Madrigal Pharmaceuticals, Inc. have?

Cash and debt help frame MDGL's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.